March 9, 2020 / 12:22 PM / 22 days ago

BRIEF-Revolution Medicines To Support Netherlands Cancer Institute On A Combination Clinical Study

March 9 (Reuters) - Revolution Medicines Inc:

* NEW CLINICAL TRIAL EXPLORING REVOLUTION MEDICINES’ INVESTIGATIONAL SHP2 INHIBITOR RMC-4630 IN COMBINATION WITH AN ERK INHIBITOR ANNOUNCED BY NETHERLANDS CANCER INSTITUTE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below